Data Unveil

Overview

Data Unveil is a data and analytics vendor for biopharma commercial teams that need to make hub, specialty-pharmacy, distribution, reimbursement, and patient-services data usable. Its public positioning is narrower than a scaled claims, RWE, or CRM platform: the practical buyer use case is channel-data aggregation, normalization, patient-journey reporting, and field reimbursement workflow support.

For a launch team, Data Unveil belongs in the shortlist when operational channel data are fragmented across hubs, specialty pharmacies, and access partners, and the manufacturer needs cleaner reporting without rebuilding its entire data stack. It should be compared against enterprise platforms only for the specific workflow being purchased; IQVIA, Veeva, Komodo, HealthVerity, IntegriChain, Claritas Rx, MMIT, AssistRx, and CoverMyMeds solve adjacent but often broader or different problems.

Platform Capability Model

The framework below standardizes how Rx Almanac evaluates data-technology-platforms capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, Data Unveil is evaluated as data and analytics vendor for biopharma commercial teams that need to make hub, specialty-pharmacy, distribution, reimbursement, and patient-services data usable.

Capability	Buyer should compare	Data Unveil readout
Data aggregation and interoperability	Claims, EHR, CRM, pharmacy, provider, payer, and FHIR/API connectivity with normalization and identity resolution.	Core data foundation. Data Unveil is best read as a hub and specialty-pharmacy channel-data aggregation and normalization vendor.
Commercial analytics and patient finding	Targeting, segmentation, patient finding, provider analytics, referral leakage, and opportunity sizing.	Documented but narrow. The relevant use case is patient-journey and channel-performance reporting, not broad enterprise RWE or claims analytics.
Workflow automation and CRM integration	Case workflows, field workflows, CRM, task automation, document handling, and operational queue management.	Documented in profile. FRM Workflow is the buyer-facing workflow angle; diligence should test what integrates with CRM or field tools.
Provider, payer, and pharmacy network connectivity	Network reach across HCPs, payers, pharmacies, labs, health systems, and transaction endpoints.	Confirm network reach in the RFP. The useful question is which hub, specialty-pharmacy, payer, and distribution data feeds are included versus client-provided.
AI, NLP, and unstructured data extraction	Conversation intelligence, document AI, NLP extraction, predictive models, and model monitoring.	Not the main buying reason for Data Unveil; validate only if the SOW includes ai, nlp, and unstructured data extraction.
Security, compliance, and governance	HIPAA, SOC2, data-use controls, auditability, consent, privacy, and regulated-workflow safeguards.	Confirm governance control. Buyers should request current SOC 2 / HIPAA evidence, audit scope, data-use rights, and Datavant linkage details.
Reporting, dashboards, and data delivery	Dashboards, exports, APIs, scheduled reporting, and downstream feeds to analytics or operating teams.	Core reporting layer. SCRAII is positioned as the reporting / analytics layer for patient journey and channel performance views.

Buyer Fit

• When it belongs in the set: Include Data Unveil when the immediate problem is hub / SP data cleanup, patient-journey reporting, FRM workflow visibility, or channel-performance analytics.
• Therapy and product fit: Best fit is specialty and biologic brands where patient status, referral, dispense, reimbursement, and field reimbursement data span multiple partners.
• Commercial fit: Pricing is Subscription, so compare platform fees, implementation work, data-source costs, Datavant linkage costs, report buildout, and ongoing support.
• Operating fit: Data Unveil is more likely to augment a hub, specialty pharmacy, CRM, or data lake than replace the manufacturer’s enterprise data platform.
• Launch diligence: Confirm data rights, refresh cadence, source mapping, integration effort, user workflow fit, security evidence, and named implementation references.

Differentiators

• Channel-data focus: Data Unveil’s strongest buyer-facing angle is hub and specialty-pharmacy data normalization rather than broad claims/RWE coverage.
• SCRAII reporting: SCRAII gives buyers a named analytics layer to evaluate for patient journey, channel performance, and reimbursement reporting.
• FRM Workflow: FRM Workflow makes the page relevant to access and field reimbursement teams, not just data / IT owners.
• Datavant linkage: The Datavant partnership gives Data Unveil a public privacy-preserving linkage story, though buyers should verify what linkage is included in scope.
• Smaller-vendor posture: Data Unveil may be more focused and flexible than large enterprise platforms, but buyers should diligence references and data coverage carefully.

RFP Questions

• Which hub, specialty-pharmacy, distribution, claims, payer, and patient-services feeds are included, and which require separate licensing or client provision?
• What does SCRAII provide out of the box versus through custom report development?
• What FRM Workflow actions are tracked, assigned, integrated, or automated?
• How does the Datavant relationship work operationally, and what matching, tokenization, and privacy controls are in scope?
• What data refresh cadence, data-quality checks, error-resolution workflow, and audit logs are included?
• Which CRM, data-lake, hub, or field tools does Data Unveil integrate with in production?
• What current security evidence, SOC 2 scope, HIPAA controls, and implementation references can the vendor provide?

Recent Activity

• 2026: Data Unveil has public-source support for its Datavant partnership and company-described analytics / channel-data positioning.
• 2026: Recent public and market-intelligence review did not produce strong direct evidence for named customers, brand counts, or detailed SCRAII / FRM Workflow adoption; treat scale and security-certification claims as diligence items.
• 2026: Broader market materials continue to show a crowded and much larger data-platform backdrop led by IQVIA, Veeva, and other enterprise analytics vendors.